Andrei et al 2025 — Repurposed agents in diabetic neuropathy: metformin + pioglitazone in cross-condition class
One-paragraph summary
Narrative review consolidating the main pathophysiological pathways involved in diabetic neuropathy (DN) — metabolic imbalance, oxidative stress, neuroinflammation, ion channel dysfunction, mitochondrial impairment — and the broad pharmacological-repurposing landscape targeting these pathways. The reviewed drug-class taxonomy includes antidiabetics (metformin, empagliflozin, gliclazide, semaglutide, pioglitazone), antihypertensives (amlodipine, telmisartan, aliskiren, rilmenidine), lipid-lowering agents (atorvastatin, alirocumab), anticonvulsants (topiramate, retigabine), antioxidant / neuroprotective agents (melatonin), and muscarinic receptor antagonists (pirenzepine, oxybutynin, atropine). All have shown promising preclinical results in rodent DN models. For the project, this paper consolidates the cross-condition framing for metformin and pioglitazone in the v0.3.1 §12.9 arm — both drugs are part of a broader anti-diabetic repurposing class with documented preclinical neuropathy efficacy. Useful citation reinforcement; doesn't directly close any new gap but anchors the repurposing strategy within a wider drug-class context. The review's mention of GLP-1 agonists (semaglutide) and SGLT2 inhibitors (empagliflozin) suggests additional candidate companion arms beyond pioglitazone for the v0.3.x cure-path program — a potential future expansion direction.
Claims as triples
metformin — bridges → small_fiber_neuropathy[evidence: review of preclinical DN model efficacy; confidence: bridging]pioglitazone — bridges → small_fiber_neuropathy[evidence: review of preclinical DN model efficacy; confidence: bridging]pioglitazone — modulates → neuroinflammation_glial[evidence: review's anti-inflammatory mechanism framing for PPAR-γ class; confidence: bridging (reinforces existing edge from Qin 2026)]
Methods note
Narrative review. Pathway-by-pathway taxonomy of DN mechanism + drug-class-by-drug-class taxonomy of preclinical-efficacious repurposed agents. No new primary data. Useful for systematic understanding of the broader repurposing landscape.
Limitations
- Review-level evidence; no FM-direct data. Translation to FM rests on the SFN/DN-FM phenotype overlap (which is well-established at the small-fiber-neuropathy level for both conditions).
- Single-laboratory review — Andrei et al, single Romanian institution; not a Cochrane-level systematic synthesis. Use for context, not adjudication.
- Mostly preclinical evidence cited. Translation to human DN, much less human FM, is by extrapolation.
Open questions raised
- Do GLP-1 agonists (semaglutide, tirzepatide) operate through analogous AMPK / mitochondrial-quality-control mechanisms as metformin in FM context? Could be a candidate companion arm; established safety in metabolic disease.
- Do SGLT2 inhibitors (empagliflozin, dapagliflozin) — which have cardiovascular benefits in heart failure — also have FM-relevant effects? Cross-condition mechanism overlap with metformin's mitochondrial axis.
- Is melatonin (mentioned in the review as antioxidant / neuroprotective) relevant to FM? The Q5 (glymphatic + sleep + neuroinflammation) bridge already implicates melatonin tangentially.
Triangulation notes
- Reinforces v0.3.1 §12.9 metformin + pioglitazone framing by placing both drugs in a broader repurposing landscape. Useful citation backing.
- Suggests new candidate companion arms — GLP-1 agonists and SGLT2 inhibitors as candidates for HERV+/metabolic-syndrome FM subset. Not currently in cure-path framework but worth tracking.
- Cross-condition validation for the project's drug-repurposing strategy: the same metformin-and-related-drugs cluster shows preclinical efficacy in DN, MS, FM mouse models — multiple chronic-pain / chronic-disease conditions converging on the same drug class.
Bridges
- B17 reinforced — metformin / AMPK-activator class ↔ FM via cross-condition repurposing landscape (now extending to DN).
- B20 reinforced — pioglitazone / PPAR-γ-agonist class ↔ FM via shared DN-relevant mechanism.
- New candidate B24 — broad anti-diabetic repurposing class (GLP-1 agonists, SGLT2 inhibitors) as candidate companion arms for HERV+/metabolic-syndrome FM. Not currently a project priority but worth tracking.